Distinct properties and advantages of a novel peroxisome proliferator-activated protein γ selective modulator

Molecular Endocrinology

Volumn 17, Issue 4, 2003, Pages 662-676

  Berger, Joel P ^a   Petro, Ann E ^b   Macnaul, Karen L ^a   Kelly, Linda J ^a   Zhang, Bei B ^a   Richards, Karen ^a   Elbrecht, Alex ^a   Johnson, Bruce A ^a   Zhou, Gaochao ^a   Doebber, Thomas W ^a   Biswas, Chhabi ^a   Parikh, Mona ^a   Sharma, Neelam ^a   Tanen, Michael R ^a   Thompson, G Marie ^a   Ventre, John ^a   Adams, Alan D ^a   Mosley, Ralph ^a   Surwit, Richard S ^b   Moller, David E ^a  

^a MERCK RESEARCH LABORATORIES   (United States)

^b DUKE UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

1 (4 CHLOROBENZYL) 5 CHLORO 3 PHENYLTHIOBENZ 2 YLCARBOXYLIC ACID; 3 [4 (3 PHENYL 7 PROPYLBENZISOXAZOL 6 YL)OXY]BUTYLOXYPHENYLACETIC ACID; 3 CHLORO 4 [3 (3 PHENYL 7 PROPYLBENZOFURAN 6 YL)OXYPROPYL]THIOPHENYLACETIC ACID; 3 CHLORO 4 [3 (3 TRIFLUOROMETHYL 7 PROPYLBENZISOXAZOL 6 YL)OXYPROPYL]THIOPHENYLACETIC ACID; 3 CHLORO 4 [3 [2 PROPYL 3 HYDROXY 4 (1 HYDROXYIMINOPROPYL)]PHENOXYPROPYL]THIOPHENYLACETIC ACID; 5 [4 [2 (5 METHYL 2 PHENYL 4 OXAZOLY) 2 HYDROXYETHOXY]BENZYL] 2,4 THIAZOLIDINEDIONE; ALPHA (2 PHENYLOXOMETHYLPHENYLAMINO) BETA [4 [2 (2 PHENYL 5 METHYLOXAZOL 4 YL)ETHOXY]]PHENYLPROPIONIC ACID; ANTIDIABETIC AGENT; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR AGONIST; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR ALPHA; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR DELTA; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; PIOGLITAZONE; ROSIGLITAZONE; UNCLASSIFIED DRUG;

ADIPOCYTE; ADIPOSE TISSUE; ANIMAL CELL; ARTICLE; BODY COMPOSITION; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG ACTIVITY; DRUG ANTAGONISM; DRUG EFFECT; DRUG EFFICACY; DRUG IDENTIFICATION; DRUG POTENCY; DRUG RECEPTOR BINDING; DRUG STRUCTURE; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION; HEART VENTRICLE HYPERTROPHY; HYPERGLYCEMIA; HYPERINSULINEMIA; LIGAND BINDING; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN CONFORMATION; PROTEIN STABILITY; TRANSCRIPTION INITIATION; WEIGHT REDUCTION;

ADIPOCYTES; ADIPOSE TISSUE; ANIMALS; CARDIOMEGALY; CELLS, CULTURED; GENE EXPRESSION REGULATION; HYPERGLYCEMIA; INDOLES; INSULIN RESISTANCE; MAGNETIC RESONANCE SPECTROSCOPY; MALE; MICE; MICE, INBRED C57BL; MODELS, MOLECULAR; PROTEIN CONFORMATION; RECEPTORS, CYTOPLASMIC AND NUCLEAR; SULFIDES; TRANSCRIPTION FACTORS; WEIGHT GAIN;

ANIMALIA;

EID: 12444273748     PISSN: 08888809     EISSN: None     Source Type: Journal    
DOI: 10.1210/me.2002-0217     Document Type: Article

References (51)

1. Berger J, Moller DE 2002 The mechanism of action of PPARs. Annu Rev Med 53:409-435
2. Tontonoz P, Hu E, Spiegelman BM 1994 Stimulation of adipogenesis in fibroblasts by PPAR γ2, a lipid activated transcription factor. Cell 79:1147-1156
3. Rosen ED, Sarraf P, Troy AE, Bradwin G, Moore K, Milstone DS, Spiegelman BM, Mortensen RM 1999 PPARγ is required for the differentiation of adipose tissue in vivo and in vitro. Mol Cell 4:611-617
4. Barak Y, Nelson MC, Ong ES, Jones YZ, Ruiz-Lozano P, Chien KR, Koder A, Evans RM 1999 PPAR γ is required for placental, cardiac, and adipose tissue development. Mol Cell 4:585-595
5. Kubota N, Terauchi Y, Miki H, Tamemoto H, Yamauchi T, Komeda K, Satoh S, Nakano R, Ishii C, Sugiyama T, Eto K, Tsubamoto Y, Okuno A, Murakami K, Sekihara H, Hasegawa G, Naito M, Toyoshima Y, Tanaka S, Shiota K, Kitamura T, Fujita T, Ezaki O, Aizawa S, Nagai R, Tobe K, Kimura S, Kadowaki T 1999 PPARγ mediates high fat diet-induced adipocyte hypertrophy and insulin resistance. Mol Cell 4:597-609
6. IJpenberg A, Jeannin E, Wahli W, Desvergne B 1997 Polarity and specific sequence requirements of peroxisome proliferator-activated receptor (PPAR)/retinoid X receptor heterodimer binding to DNA. A functional analysis of the malic enzyme gene PPAR response element. J Biol Chem 272:20108-20117
7. Wilison TM, Brown PJ, Sternbach DD, Henke BR 2000 The PPARs: from orphan receptors to drug discovery. J Med Chem 43:527-550
8. Saltiel AR, Olefsky JM 1996 Thiazolidinediones in the treatment of insulin resistance and type II diabetes. Diabetes 45:1661-1669
9. Willson TM, Cobb JE, Cowan DJ, Wiethe RW, Correa ID, Prakash SR, Beck KD, Moore LB, Kliewer SA, Lehmann JM 1996 The structure-activity relationship between peroxisome proliferator-activated receptor γ agonism and the antihyperglycemic activity of thiazolidinediones. J Med Chem 39:665-668
10. Berger J, Bailey P, Biswas C, Cullinan CA, Doebber TW, Hayes NS, Saperstein R, Smith RG, Leibowitz MD 1996 Thiazolidinediones produce a conformational change in peroxisomal proliferator-activated receptor-γ binding and activation correlate with antidiabetic actions in db/db mice. Endocrinology 137:4189-4195
11. Reginato MJ, Lazar MA 1999 Mechanisms by which thiazolidinediones enhance insulin action. Trends Endocrinol Metab 10:9-13
12. Yamauchi T, Kamon J, Waki H, Murakami K, Motojima K, Komeda K, Ide T, Kubota N, Terauchi Y, Tobe K, Miki H, Tsuchida A, Akanuma Y, Nagai R, Kimura S, Kadowaki T 2001 The mechanisms by which both heterozygous peroxisome proliferator-activated receptor γ (PPARγ) deficiency and PPARγ agonist improve insulin resistance. J Biol Chem 276:41245-41254
13. Hanefeld M, Belcher G 2001 Safety profile of pioglitazone. Int J Clin Practice Sept.:27-31
14. Sorbera LA, Rabasseda X, Castanet J 1998 Rosiglitazone maleate. Drugs of the Future 23:977-985
15. Wooltoron E 2002 Rosiglitazone (Avandia) and pioglitazone (Actos) and heart failure. Can Med Assoc J 166:219
16. Katzenellenbogen JA, O'Malley BW, Katzenellenbogen BS 1996 Tripartite steroid hormone receptor pharmacology: interaction with multiple effector sites as a basis for the cell- and promoter-specific action of these hormones. Mol Endocrinol 10:119-131
17. McDonnell DP, Clemm DL, Hermann T, Goldman ME, Pike JW 1995 Analysis of estrogen receptor function in vitro reveals three distinct classes of antiestrogens. Mol Endocrinol 9:659-669
18. Guido EC, Delorme EO, Clemm DL, Stein RB, Rosen J, Miner JN 1996 Determinants of promoter-specific activity by glucorticoid receptor. Mol Endocrinol 10:1178-1190
19. Saltiel AR 2001 New perspectives into the molecular pathogenesis and treatment of type 2 diabetes. Cell 104:517-529
20. Berger J, Leibowitz MD, Doebber TW, Elbrecht A, Zhang B, Zhou G, Biswas C, Cullinan CA, Hayes NS, Li Y, Tanen M, Ventre J, Wu MS, Berger GD, Mosley R, Marquis R, Santini C, Sahoo SP, Tolman RL, Smith RG, Moller DE 1999 Novel PPARγ and PPARδ ligands produce distinct biological effects. J Biol Chem 274:6718-6725
21. Spiegelman BM 1998 PPAR-γ: adipogenic regulator and thiazolidinedione receptor. Diabetes 47:507-514
22. Szalkowski D, White-Carrington S, Berger J, Zhang B 1995 Antidiabetic thiazolidinediones block the inhibitory effect of tumor necrosis factor-α on differentiation, insulin-stimulated glucose uptake, and gene expression in 3T3-L1 cells. Endocrinology 136:1474-1481
23. Berger J, Patel HV, Woods J, Hayes NS, Parent SA, Clemas J, Leibowitz MD, Elbrecht A, Rachubinski RA, Capone JP, Moller DE 2000 A PPARγ mutant serves as a dominant negative inhibitor of PPAR signaling and is localized in the nucleus. Mol Cell Endocrinol 162:57-67
24. Eibrecht A, Chen Y, Cullinan CA, Hayes N, Leibowitz M, Moller DE, Berger J 1996 Molecular cloning, expression and characterization of human peroxisome proliferator activated receptors γ1 and γ2. Biochem Biophys Res Commun 224:431-437
25. Elbrecht A, Chen Y, Adams A, Berger J, Griffin P, Klatt T, Zhang B, Menke J, Zhou G, Smith RG, Moller DE 1999 L-764406 is a partial agonist of human peroxisome proliferator-activated receptor γ. The role of Cys313 in ligand binding. J Biol Chem 274:7913-7922
26. Johnson BA, Wilson EM, Li Y, Moller DE, Smith RG, Zhou G 2000 Ligand-induced stabilization of PPARγ monitored by NMR spectroscopy: implications for nuclear receptor activation. J Mol Biol 298:187-194
27. Gerhold DL, Liu F, Jiang G, Li Z, Xu J, Lu M, Sachs JR, Bagchi A, Fridman A, Holder DJ, Doebber TW, Berger J, Elbrecht A, Moller DE, Zhang BB 2002 Gene expression profile of adipocyte differentiation and its regulation by peroxisome proliferator-activated receptor-γ agonists. Endocrinology 143:2106-2118
28. McKenna NJ, O'Malley BW 2000 From ligand to response: generating diversity in nuclear receptor co-regulator function. J Steroid Biochem Mol Biol 74:351-356
29. Moller DE, Greene DA 2001 Peroxisome proliferator-activated receptor (PPAR) γ agonists for diabetes. Adv Protein Chem 56:181-212
30. Lebovitz HE 2002 Differentiating members of the thiazolidinedione class: a focus on safety. Diabetes Metab Res Rev 18:S23-S29
31. Schoonjans K, Auwerx J 2000 Thiazolidinediones: an update. Lancet 355:1008-1010
32. Barroso I, Gurnell M, Crowley VEF, Agostini M, Schwabe JW, Soos MA, Maslen GL, Williams TD, Lewis H, Schafer AJ, Chatterjee VK, O'Rahilly S 1999 Dominant negative mutations in human PPARγ associated with severe insulin resistance, diabetes mellitus, and hypertension. Nature 402:880-883
33. Oberfield JL, Collins JL, Holmes CP, Goreham DM, Cooper JP, Cobb JE, Lenhard JM, Hull-Ryde EA, Mohr CP, Blanchard SG, Parks DJ, Moore LB, Lehmann JM, Plunket K, Miller AB, Milburn MV, Kliewer SA, Willson TM 1999 A peroxisome proliferator-activated receptor γ ligand inhibits adipocyte differentiation. Proc Natl Acad Sci USA 96:6102-6106
34. Mukherjee R, Hoener PA, Jow L, Bilakovics J, Klausing K, Mais DE, Faulkner A, Croston GE, Paterniti Jr JR 2000 A selective peroxisome proliferator-activated receptor-γ (PPARγ) modulator blocks adipocyte differentiation but stimulates glucose uptake in 3T3-L1 adipocytes. Mol Endocrinol 14:1425-1433
35. Wright HM, Clish CB, Mikami T, Hauser S, Yanagi K, Hiramatsu R, Serhan CN, Spiegelman BM 2000 A synthetic antagonist for the peroxisome proliferator-activated receptor γ inhibits adipocyte differentiation. J Biol Chem 275:1873-1877
36. Rocchi S, Picard F, Vamecq J, Gelman L, Potier N, Zeyer D, Dubuquoy L, Bac P, Champy MF, Plunket KD, Leesnitzer LM, Blanchard SG, Desreumaux P, Moras D, Renaud JP, Auwerx J 2001 A unique PPARγ ligand with potent insulin-sensitizing yet weak adipogenic activity. Mol Cell 8:737-747
37. Xu L, Glass CK, Rosenfeld MG 1999 Coactivator and corepressor complexes in nuclear receptor function. Curr Opin Genet Dev 9:140-147
38. Green AR, Parrott EL, Butterworth M, Jones PS, Greaves P, White IN 2001 Comparisons of the effects of tamoxifen, toremifene and raloxifene on enzyme induction and gene expression in the ovariectomised rat uterus. J Endocrinol 170:555-564
39. Surwit RS, Kuhn CM, Cochrane C, McCubbin JA 1988 Diet-induced type II diabetes in C57BL/6J mice. Diabetes 37:1163-1167
40. Surwit RS, Feinglos MN, Rodin J, Sutherland A, Petro AE, Opara EC, Kuhn CM, Rebuffe-Scrive M 1995 Differential effects of fat and sucrose on the development of obesity and diabetes in C57BL/6J and A/J mice. Metabolism 44:645-651
41. Okuno A, Tamemoto H, Tobe K, Ueki K, Mori Y, Iwamoto K, Umesono K, Akanuma Y, Fujiwara T, Horikoshi H, Yazaki Y, Kadowaki T 1998 Troglitazone increases the number of small adipocytes without the changes of white adipose tissue mass in obese Zucker rats. J Clin Invest 101:1354-1361
42. Akazawa S, Sun F, Ito M, Kawasaki E, Eguchi K 2000 Efficacy of troglitazone on body fat distribution in type 2 diabetes. Diabetes Care 23:1067-1071
43. Fruebis J, Tsao TS, Javorschi S, Ebbets-Reed D, Erickson MR, Yen FT, Bihain BE, Lodish HF 2001 Proteoiytic cleavage product of 30-kDa adipocyte complement-related protein increases fatty acid oxidation in muscle and causes weight loss in mice. Proc Natl Acad Sci USA 98:2005-2010
44. Combs TP, Berg AH, Obici S, Scherer PE, Rossetti L 2001 Endogenous glucose production is inhibited by the adipose-derived protein Acrp30. J Clin Invest 108:1875-1881
45. Hotamisligil GS, Shargill NS, Spiegelman BM 1993 Adipose expression of tumor necrosis factor-α: direct role in obesity-linked insulin resistance. Science 259:87-91
46. Collins JL, Blanchard SG, Boswell GE, Charifson PS, Cobb JE, Henke BR, Hull-Ryde EA, Kazmierski WM, Lake DH, Leesnitzer LM, Lehmann J, Lenhard JM, Orband-Miller LA, Gray-Nunez Y, Parks DJ, Plunkett KD, Tong WQ 1998 N-(2-Benzoylphenyl)-L-tyrosine PPARγ agonists. 2. Structure-activity relationship and optimization of the phenyl alkyl ether moiety. J Med Chem 41:5037-5054
47. Cheng Y, Prusoff WH 1973 Relationship between the inhibition constant (K1) and the concentration of inhibitor which causes 50 per cent inhibition (150) of an enzymatic reaction. Biochem Pharmacol 22:3099-3108
48. Zhang B, Berger J, Hu E, Szaikowski D, White-Carrington S, Spiegelman BM, Moller DE 1996 Negative regulation of peroxisome proliferator-activated receptor-γ gene expression contributes to the anti-adipogenic effects of tumor necrosis factor-α. Mol Endocrinol 10:1457-1466
49. Koradi R, Billeter M, Wuthrich K 1996 MOLMOL: a program for display and analysis of macromolecular structures. J Mol Graph 14:29-32; 51-55
50. Lockhart DJ, Dong H, Byrne MC, Follettie MT, Gallo MV, Chee MS, Mittmann M, Wang C, Kobayashi M, Horton H, Brown EL 1996 Expression monitoring by hybridization to high-density oligonucleotide arrays. Nat Biotechnol 14:1675-1680
51. Salmon DM, Flatt JP 1985 Effect of dietary fat content on the incidence of obesity among ad libitum fed mice. Int J Obes 9:443-449